Teva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target at Credit Suisse Group

Credit Suisse Group set a $23.00 price objective on Teva Pharmaceutical Industries (NYSE:TEVA) in a research note released on Wednesday. The firm currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. BTIG Research raised their price target on shares of Teva Pharmaceutical Industries to $20.00 in a report on Friday, December 15th. Goldman Sachs upgraded shares of Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $20.00 price target on the stock in a report on Friday, December 15th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a hold rating to a buy rating in a report on Tuesday, December 5th. Citigroup upgraded shares of Teva Pharmaceutical Industries from a neutral rating to a buy rating and set a $24.00 price target on the stock in a report on Thursday, January 4th. Finally, Mizuho upgraded shares of Teva Pharmaceutical Industries from a neutral rating to a buy rating and raised their price target for the company from $19.12 to $23.00 in a report on Tuesday, January 9th. Eleven investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries presently has a consensus rating of Hold and a consensus target price of $19.67.

How to Become a New Pot Stock Millionaire

Teva Pharmaceutical Industries stock opened at $16.88 on Wednesday. The firm has a market cap of $17,510.62, a PE ratio of 4.30, a price-to-earnings-growth ratio of 1.50 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.58 and a debt-to-equity ratio of 1.91. Teva Pharmaceutical Industries has a 1-year low of $10.85 and a 1-year high of $33.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, February 8th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.14. The business had revenue of $5.46 billion for the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. Teva Pharmaceutical Industries’s revenue for the quarter was down 15.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.38 EPS. research analysts expect that Teva Pharmaceutical Industries will post 2.3 EPS for the current year.

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 5,050 shares of the firm’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the sale, the executive vice president now directly owns 44,517 shares in the company, valued at approximately $876,094.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 10,734 shares of company stock worth $204,795 over the last 90 days. Company insiders own 7.10% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC grew its position in Teva Pharmaceutical Industries by 66.5% in the 4th quarter. Teachers Advisors LLC now owns 3,221,405 shares of the company’s stock worth $61,046,000 after purchasing an additional 1,286,637 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Teva Pharmaceutical Industries by 14.7% during the 3rd quarter. New York State Common Retirement Fund now owns 780,292 shares of the company’s stock valued at $13,733,000 after acquiring an additional 100,200 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Teva Pharmaceutical Industries by 1.0% during the 3rd quarter. California State Teachers Retirement System now owns 613,392 shares of the company’s stock valued at $10,796,000 after acquiring an additional 5,860 shares in the last quarter. Millennium Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 56.6% during the 4th quarter. Millennium Management LLC now owns 2,965,936 shares of the company’s stock valued at $56,204,000 after acquiring an additional 1,071,583 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Teva Pharmaceutical Industries by 1,498.9% during the 4th quarter. Caisse DE Depot ET Placement DU Quebec now owns 328,228 shares of the company’s stock valued at $6,220,000 after acquiring an additional 307,700 shares in the last quarter. Institutional investors own 58.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Teva Pharmaceutical Industries (TEVA) Given a $23.00 Price Target at Credit Suisse Group” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3339926/teva-pharmaceutical-industries-teva-given-a-23-00-price-target-at-credit-suisse-group.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Boyd Gaming  Lowered to Sell at Zacks Investment Research
Boyd Gaming Lowered to Sell at Zacks Investment Research
Baidu  Downgraded by Zacks Investment Research
Baidu Downgraded by Zacks Investment Research
$177.37 Million in Sales Expected for Omnicell Technologies  This Quarter
$177.37 Million in Sales Expected for Omnicell Technologies This Quarter
Hess  Hits New 1-Year High and Low at $59.56
Hess Hits New 1-Year High and Low at $59.56
Cadence Bancorp  Sets New 52-Week High and Low at $29.40
Cadence Bancorp Sets New 52-Week High and Low at $29.40
Short Interest in Lilis Energy  Increases By 6.9%
Short Interest in Lilis Energy Increases By 6.9%


© 2006-2018 Ticker Report. Google+.